<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3009211088
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Kesimpta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OFATUMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4344.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA SCHWEIZ AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What KESIMPTA is: </strong></p><p>KESIMPTA contains the active substance ofatumumab.</p><p>Ofatumumab belongs to a group of medicines called monoclonal antibodies.</p><p><strong>&nbsp;</strong></p><p><strong>What KESIMPTA is used for</strong></p><p>KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.</p><p>&nbsp;</p><p><strong>How KESIMPTA works:</strong></p><p>Kesimpta works by attaching to a target called CD20 on the surface of B cells. B cells are a type of white blood cell which are part of the immune system and which play a role in multiple sclerosis. Kesimpta targets and removes the B cells and thereby reduces the chance of having a relapse, relieves symptoms and slows down the progression of the disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp; Before treatment with KESIMPTA</strong></p><p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information contained in this leaflet</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take KESIMPTA</strong></p><p>&nbsp;</p><p>If you if you are allergic to ofatumumab or any of the other ingredients of this medicine (see section 6).or life-threatening injectionrelated reaction to KESIMPTA.<br />&bull; Have an active hepatitis B virus infection.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with KESIMPTA</strong></p><p>Tell your healthcare provider about all of your medical conditions, including if you:<br />&bull; if you have been told that you have severe problems with your immune system, your doctor may decide that you cannot be given KESIMPTA<br />&bull; Have or think you have an infection, including HBV or PML. [See section Possible side effects]<br />&bull; Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.<br />&bull; Have had a recent vaccination or are scheduled to receive any vaccinations.<br />o You should receive any required &lsquo;live&rsquo; or &lsquo;live-attenuated&rsquo; vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive &lsquo;live&rsquo; or &lsquo;live-attenuated&rsquo; vaccines while you are being treated with KESIMPTA and until your healthcare provider<br />tells you that your immune system is no longer weakened.<br />o Whenever possible, you should receive any &lsquo;non-live&rsquo; vaccines at least 2 weeks before you start treatment with KESIMPTA.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking other medicines, herbal or dietary supplements </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br />Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p><p><strong>&nbsp;</strong></p><p><strong>d. Children and adolescents</strong><br />Do not give this medicine to children and adolescents below 18 years of age because Kesimpta has not yet been studied in this age group.</p><p>&nbsp;</p><p><strong>e.Pregnancy and breast-feeding <em>&nbsp;</em></strong></p><p>Pregnancy<br />It is not known if KESIMPTA will harm your unborn baby.<br />For females of childbearing potential, please be advised to use effective contraception while receiving KESIMPTA and for 6 months after the last treatment of KESIMPTA.<br />Talk with your healthcare provider about what birth control method is right for you during this time.</p><p>Breast-feeding<br />It is not known if KESIMPTA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take KESIMPTA.</p><p>Vaccination of newborn babies<br />Ask your doctor or pharmacist for advice before vaccinating your newborn if you have used Kesimpta during your<br />pregnancy.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>Kesimpta is unlikely to affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. </strong><strong>How to use KESIMPTA</strong><strong> </strong></p><p><strong>How much KESIMPTA to take</strong></p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>How much Kesimpta to use and how often to use it </strong></p><p>Do not exceed the dose prescribed by your doctor.</p><p>- The initial dose is 20 mg Kesimpta administered by subcutaneous injection at weeks 0, 1 and 2.</p><p>There is no injection at week 3.</p><p>- Starting at week 4 and then every month, the recommended dose is 20 mg Kesimpta administered by subcutaneous injection.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Time </strong></p></td><td style="vertical-align:top"><p><strong>Dose </strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 0 (beginning of treatment)</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Week 1</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Week 4</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>How to use KESIMPTA</strong></p><p>Kesimpta is given by subcutaneous injection (injection under your skin).&nbsp;in your thigh or stomach-area (abdomen) by you or a caregiver. A caregiver may also give you an injection of KESIMPTA in your upper outer arm.</p><p>The first injection should be administered under the guidance of a healthcare professional.</p><p>Kesimpta pre-filled pens are for single use only.</p><p>Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars or stretch marks.</p><p>For detailed instructions on how to inject Kesimpta, see &ldquo;Instructions for use of Kesimpta SensoReady pen&rdquo; at the end of this leaflet.</p><p><strong>a.If you use more KESIMPTS than you should</strong></p><p>If you have injected too much Kesimpta, contact your doctor right away.</p><p><strong>&nbsp;</strong></p><p><strong>b.. If you forget to use KESIMPTA</strong></p><p>If you miss an injection of KESIMPTA at Week 0, 1, or 2, talk to your healthcare provider. If you miss a monthly injection, it should be administered as soon as possible without waiting until the next scheduled dose. Subsequent doses should be administered at the recommended intervals.&nbsp;<strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>c..if you stop using KESIMPTA</strong></p><p>Do not stop using Kesimpta or change your dose without talking with your doctor.</p><p>Some side effects can be related to having a low level of B cells in your blood. After you stop treatment with Kesimpta your blood level of B cells will gradually increase to normal. This can take several months. During this time some side effects described in this leaflet may still occur.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The side effects of Kesimpta are listed below. Most are mild to moderate and will generally disappear after a few days to a few weeks of treatment. If any of these side effects becomes severe, tell your doctor, pharmacist or nurse.</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p>- upper respiratory tract infection, with symptoms such as sore throat and runny nose&nbsp;headache.<br />&bull; Headache<br />KESIMPTA can cause serious side effects, including:<br />&bull; <strong>Infections</strong>. Serious infections, which can be life-threatening or cause death, can happen during treatment with<br />KESIMPTA. If you have an active infection, your healthcare provider should delay your treatment with KESIMPTA<br />until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may<br />increase your risk of getting infections.<br />Tell your healthcare provider right away if you have any infections or get any symptoms, including painful and frequent<br />urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.<br /><strong>&bull; Hepatitis B virus (HBV) reactivation.</strong> Before starting treatment with KESIMPTA, your healthcare provider will do<br />blood tests to check for HBV. If you have ever had HBV infection, the HBV may become active again during or after<br />treatment with KESIMPTA. Hepatitis B virus becoming active again (called reactivation) may cause serious liver<br />problems, including liver failure or death. You should not receive KESIMPTA if you have active hepatitis B liver<br />disease. Your healthcare provider will monitor you for HBV infection during and after you stop using KESIMPTA.<br />Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part of your eyes<br />during treatment with KESIMPTA.<br />&bull;<strong> Progressive Multifocal Leukoencephalopathy (PML)</strong>. PML may happen with KESIMPTA. PML is a rare, serious<br />brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability.<br />Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These may<br />include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking<br />and memory which may lead to confusion and personality changes.<br />&bull;<strong> Weakened immune system.</strong> KESIMPTA taken before or after other medicines that weaken the immune system could<br />increase your risk of getting infections.<br />&bull;<strong> Injection-related reaction</strong>s. Injection-related reactions are a common side effect of KESIMPTA. Injecting<br />KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injection<br />and with later injections. There are two kinds of reactions:<br />o at or near the injection site: redness of the skin, swelling, itching and pain. Talk with your healthcare provider if you<br />have any of these signs and symptoms.<br />o that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills,<br />tiredness, rash, hives, trouble breathing, swelling of the face, eyelids, lips, mouth, tongue and throat, and feeling faint,<br />or chest tightness. Contact your healthcare provider right away if you experience any of these signs and symptoms,&nbsp;especially if they become worse or you have new severe signs of reactions after subsequent injections. It could be a<br />sign of an allergic reaction, which can be serious.<br /><strong>&bull; Low immunoglobulins</strong>. KESIMPTA may cause a decrease in some types of antibodies. Your healthcare provider will<br />do blood tests to check your blood immunoglobulin levels.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>Keep the pen(s) in the outer carton in order to protect from light. Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze and do not shake.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. What KESIMPTA contains</strong></p><p>- The active substance is ofatumumab. Each pre-filled pen contains 20 mg ofatumumab.</p><p>- The other ingredients are L-arginine, sodium acetate trihydrate, sodium chloride, polysorbate 80, disodium edetate dihydrate, hydrochloric acid (for pH adjustment) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.What KESIMPTA looks like and contents of the pack
Kesimpta solution for injection is clear to slightly opalescent, and colourless to slightly brownish-yellow.
Kesimpta is available in unit packs containing 1 pre-filled SensoReady pen and in multipacks containing 3 (3 packs of 1) pre-filled SensoReady pens.

Not all pack sizes may be marketed 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by USFDA in 04/2024
e. To report any side effect(s):
• Saudi Arabia
Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):
o Fax: +966-11-205-7662
SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa
Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100
o Fax: +966112658107
o Email: adverse.events@novartis.com
To report any complaint(s): complaints.ksa@novartis.com
• Other GCC States:
- Please contact the relevant competent authority.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو عقار كيسيمبتا. </strong></p><p dir="RTL">يحتوي عقار كيسيمبتا على المادة الفعّالة أوفاتوموماب.</p><p dir="RTL">ينتمي أوفاتومومابإلى مجموعة من الأدوية تُسمى أجسامًا مضادة أحادية النسيلة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ماهي دواعي استعماله.</strong></p><p dir="RTL">يُستخدم عقار كيسيمبتا لعلاج الحالات الانتكاسية لمرض التصلُّب اللويحي (MS)؛ لتشمل المتلازمة السريرية المعزولة، والمرض المنتكس المتقطع، والمرض الثانوي المتطورالنشط في البالغين.</p><p dir="RTL"><strong>كيف يعمل عقار كيسيمبتا؟</strong></p><p dir="RTL">يعمل عقار كيسيمبتا عن طريق الارتباط بهدف يسمى (CD20) على سطح الخلايا البائية. الخلايا البائية هي نوع من خلايا الدم البيضاء التي هي جزء من جهاز المناعة والتي تلعب دورًا في التصلب اللويحي. يستهدف عقار كيسيمبتا الخلايا البائية ويزيلها وبالتالي يقلل من فرصة حدوث انتكاسة ويخفف الأعراض ويبطئ تقدم المرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قبل العلاج بعقار كيسيمبتا</strong></p><p dir="RTL">اتبع جميع تعليمات الطبيب بعناية. قد تختلف عن المعلومات العامة الواردة في هذه النَّشرة.</p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال عقار كيسيمبتا</strong></p><p dir="RTL">إذا كنت تعاني من حساسية تجاه أوفاتوموماب أو أيٍّ من المكونات الأخرى بهذا الدَّواء (انظر قسم 6).&nbsp;أو رد فع مفمد الحياه ناتج عن حقن كيسيمبتا.<br />&bull; إذا كنت تعاني من عموى نشطة بفيروس التفاب الكبم نوم )ب(</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الإحتياطات عند استعمال عقار كيسيمبتا</strong></p><p dir="RTL"><strong>أخبر مقدم الرعاية الصحية الخاص بك عن جميع حالاتك الطبية، بما في ذلك:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إخبارك بأن لديك مشاكل خطيرة في جهاز المناعة ، فقد يقرر طبيبك أنه لا يمكن إعطاؤك عقار كيسيمبتا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني او تعتقد انك مصاب بعدوى بما في ذلك HBV أو ] PMLانظر قسم الآثار الجانبية المحتملة[</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق أن تناولت، أو تتناول حاليًا، أو تخطط لتناول أدوية تؤثر على جهازك المناعي. هذه الأدوية يمكن أن تزيد من خطر الإصابة بالعدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصلت على التطعيم مؤخرًا أو من المقرر أن تتلقى أي تطعيمات:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتلقى أي لقاحات &quot;حية&quot; أو &quot;حية مضعفة&quot; مطلوبة قبل 4 أسابيع على الأقل من بدء العلاج باستخدام كيسيمبتا. يجب ألا تتلقى لقاحات &quot;حية&quot; أو &quot;حية مضعفة&quot; أثناء علاجك بـ كيسيمبتا وحتى يخبرك مقدم الرعاية الصحية الخاص بك أن جهازك المناعي لم يعد ضعيفًا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلما أمكن، يجب أن تتلقى أي لقاحات &quot;غير حية&quot; قبل أسبوعين على الأقل من بدء العلاج باستخدام كيسيمبتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التداخلات الدوائية من أخذ عقار كيسيمبتا مع أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى بما في ذلك الأدوية التي تصرف بدون وصفة طبية والفيتامينات والمكملات العشبية.</p><p dir="RTL">كن على معرفه بالأدوية التي تتناولها. احتفظ بقائمة بها لعرضها على مقدم الرعاية الصحية والصيدلي عندما تحصل على دواء جديد.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>د.&nbsp;&nbsp; الحمل والرضاعة</strong><strong><em> </em></strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">من غير المعروف ما إذا كان كيسيمبتا سيؤذي طفلك الذي لم يولد بعد.</p><p dir="RTL">بالنسبة للسيدات ممن لديهن القدرة على الحمل، يُنصح باستخدام وسائل منع الحمل الفعالة أثناء تلقي عقار كيسيمبتا ولمدة 6 أشهر بعد آخر جرعة من عقار كيسيمبتا.</p><p dir="RTL">تحدثي مع مقدم الرعاية الصحية الخاص بك حول طريقة منع الحمل المناسبة لك خلال هذه الفترة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">من غير المعروف ما إذا كان كيسيمبتا يفرز في حليب الأم. تحدَّثي إلى طبيبك حول الفوائد والمخاطر قبل إرضاع طفلك رضاعة طبيعية أثناء استخدام عقار كيسيمبتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تطعيم الأطفال حديثي الولادة</u></p><p dir="RTL">اطلب من طبيبك أو الصيدلي الخاص بك الاستشارة قبل تطعيم طفلك حديث الولادة إذا كنتِ قد استخدمت عقار كيسيمبتا أثناء الحمل</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يُؤثر عقار كيسيمبتا على قدرتك على القيادة واستخدام الآلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>كيفية استخدام عقار كيسيمبتا</strong></p><p dir="RTL"><strong>الكمية التي يجب تلقيها من عقار كيسيمبتا</strong></p><p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي الكمية التي يجب استخدامها من عقار كيسيمبتا وعدد مرات استخدامه</strong></p><p dir="RTL">لا تتجاوز الجرعة المُوصى بها التي وصفها لك طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الأولية هي 20 مجم من عقار كيسيمبتا، تُعطى عن طريق الحَقْن أسفل الجلد في الأسابيع 0 ،1 و2. لا يوجد حَقْن في الأسبوع 3.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدءًا من الأسبوع 4 وكل شهر بعد ذلك، تكون الجرعة الموصى بها 20 مجم من عقار كيسيمبتا وتُعطى عن طريق الحَقْن أسفل الجلد.</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الوقت </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأسبوع 0 (بداية العلاج)</p></td><td style="vertical-align:top"><p dir="RTL">20 مجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأسبوع 1</p></td><td style="vertical-align:top"><p dir="RTL">20 مجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أسبوع 2</p></td><td style="vertical-align:top"><p dir="RTL">20 مجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أسبوع 4</p></td><td style="vertical-align:top"><p dir="RTL">20 مجم</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيفية استخدام عقار كيسيمبتا</strong></p><p dir="RTL">يُعطى عقار كيسيمبتا عن طريق حَقْن أسفل الجلد (حقن تحت جلدك) في منطقة الفخذ أو المعدة (البطن) بواسطتك أو بواسطة مقدم الرعاية. قد يعطيك مقدم الرعاية أيضًا حقنة كيسيمبتا في الجزء العلوي من ذراعك الخارجي.</p><p dir="RTL">يجب إعطاء الحقنة الأولى بتوجيه من مقدم الرعاية الصحية.</p><p dir="RTL">أقلام عقار كيسيمبتا معبأة مسبقا معدة للاستخدام مرة واحدة فقط.</p><p dir="RTL">لا تحقن في المناطق التي يكون فيها الجلد طريًا أو مصابًا بكدمات أو أحمر أو متقشرًا أو صلبًا. تجنب المناطق التي تحتوي على الشامات أو الندوب أو علامات التمدد.</p><p dir="RTL">للحصول على تعليمات مفصلة حول كيفية حقن عقار كيسيمبتا، انظر قسم &quot;تعليمات استخدام قلم سينسوريدي الخاص بعقار كيسيمبتا&quot; في نهاية هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من عقار كيسيمبتا</strong></p><p dir="RTL">إذا قمت بحقن كمية كبيرة من عقار كيسيمبتا، اتصل بطبيبك فورًا.</p><p dir="RTL"><strong>ب.نسيان استعمال جرعة من عقار كيسيمبتا</strong></p><p dir="RTL">في حال نسيان جرعة كيسيمبتا في الأسبوع 0 أو 1 أو 2، فتحدث إلى مقدم الرعاية الصحية الخاص بك. في حال نسيان الجرعة الشهرية فيجب اخذها في أسرع وقت ممكن دون الانتظار حتى يحين موعد الجرعة التالية المقررة. يجب إعطاء الجرعات اللاحقة في الفترات الموصى بها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التوقف عن استعمال عقار كيسيمبتا</strong></p><p dir="RTL">لا تتوقف عن استخدام عقار كيسيمبتا أو تغير جرعتك دون التحدث إلى طبيبك.</p><p dir="RTL">من الممكن أن ترتبط بعض الآثار الجانبية بانخفاض مستوى الخلايا البائية في الدم لديك. بعد التوقف عن العلاج بعقار كيسيمبتا، سيرتفع مستوى الخلايا البائية في الدم لديك تدريجيًّا إلى المعدل الطبيعي. قد يستغرق هذا عدة أشهر. خلال هذا الوقت قد تستمر بعض الآثار الجانبية الموصوفة في هذه النشرة.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">الآثار الجانبية لعقار كيسيمبتا مُدرجة أدناه. تكون معظمها خفيفة إلى معتدلة وستختفي بصفة عامَّة بعد بضعة أيام إلى بضعة أسابيع من العلاج. إذا أصبحت هذه الآثار الجانبية شديدة، يُرجى إخبار طبيبك، أو الصيدلي، أو الممرض الخاص بك.</p><p dir="RTL">آثار جانبية شائعة<strong> </strong>جدًّا (قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التَّنفسي العلوي، مع أعراض مثل التهاب الحلق وسيلان الأنف&nbsp;والصداع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">يمكن أن يسبب كيسيمبتا آثارًا جانبية خطيرة، بما في ذلك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العدوى</strong>. يمكن أن تحدث حالات عدوى خطيرة، والتي يمكن أن تهدد الحياة أو تسبب الوفاة، أثناء العلاج باستخدام كيسيمبتا. إذا كان لديك عدوى نشطة، يجب على مقدم الرعاية الصحية الخاص بك تأخير علاجك بـ كيسيمبتا حتى تختفي العدوى. إن تناول كيسيمبتا قبل أو بعد الأدوية الأخرى التي تضعف جهاز المناعة قد يزيد من خطر الإصابة بالعدوى.</p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا كان لديك أي عدوى أو ظهرت عليك أي أعراض، بما في ذلك التبول المؤلم والمتكرر، واحتقان الأنف، وسيلان الأنف، والتهاب الحلق، والحمى، والقشعريرة، والسعال، أو آلام الجسم.</p><p dir="RTL">&bull; <strong>إعادة تنشيط فيروس التهاب الكبد</strong><strong> </strong><strong>نوع ب </strong><strong>(HBV)</strong>. قبل بدء العلاج باستخدام كيسيمبتا ، سيقوم مقدم الرعاية الصحية الخاص بك بإجراء اختبارات الدم للتحقق من وجود فيروس التهاب الكبد B ، إذا كنت قد أصبت سابقًا بعدوى فيروس التهاب الكبد B، فقد يصبح فيروس التهاب الكبد B نشطًا مرة أخرى أثناء أو بعد العلاج باستخدام كيسيمبتا. إن عودة نشاط فيروس التهاب الكبد B مرة أخرى (يسمى إعادة التنشيط) قد يسبب مشاكل خطيرة في الكبد، بما في ذلك فشل الكبد أو الوفاة. يجب ألا تتلقى كيسيمبتا إذا كان لديك فيروس التهاب الكبد B نشط. سيقوم مقدم الرعاية الصحية الخاص بك بمراقبة الإصابة بفيروس التهاب الكبد B أثناء وبعد التوقف عن استخدام كيسيمبتا.</p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا شعرت بتعب متزايد أو اصفرار بشرتك أو الجزء الأبيض من عينيك أثناء العلاج باستخدام كيسيمبتا.</p><p dir="RTL">&bull; <strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي</strong><strong>. (PML) </strong>قد يحدث PML مع كيسيمبتا. PML هو عدوى دماغية نادرة وخطيرة يسببها فيروس، قد تزداد سوءًا على مدار أيام أو أسابيع. يمكن أن يؤدي مرض PML إلى الوفاة أو الإعاقة الشديدة. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا كان لديك أي علامات أو أعراض عصبية جديدة أو متفاقمة. قد تشمل هذه الأعراض ضعفًا في جانب واحد من الجسم، وفقدان التنسيق في الذراعين والساقين، ومشاكل في الرؤية، وتغيرات في التفكير والذاكرة قد تؤدي إلى الارتباك وتغييرات في الشخصية.</p><p dir="RTL"><strong>&bull; </strong><strong>ضعف جهاز المناعة</strong>. إن تناول كيسيمبتا قبل أو بعد الأدوية الأخرى التي تضعف جهاز المناعة قد يزيد من خطر الإصابة بالعدوى.</p><p dir="RTL">&bull; <strong>التفاعلات المتعلقة بالحقن.</strong> التفاعلات المرتبطة بالحقن هي أحد الآثار الجانبية الشائعة لـ كيسيمبتا. يمكن أن يسبب حقن كيسيمبتا تفاعلات مرتبطة بالحقن والتي يمكن أن تحدث خلال 24 ساعة (يوم واحد) بعد الحقن الأول ومع الحقن اللاحقة. هناك نوعان من ردود الفعل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في مكان الحقن أو بالقرب منه: احمرار في الجلد، تورم، حكة وألم. تحدث مع مقدم الرعاية الصحية الخاص بك إذا كان لديك أي من هذه العلامات والأعراض.</p><p dir="RTL">قد يحدث ذلك عندما يتم افراز مواد معينة في الجسم: الحمى والصداع وألم في العضلات والقشعريرة والتعب والطفح الجلدي والشرى وصعوبة التنفس وتورم الوجه والجفون والشفتين والفم واللسان والحلق والشعور&nbsp; &nbsp; &nbsp; بالإغماء، أو ضيق الصدر. اتصل بمقدم الرعاية الصحية الخاص بك على الفور إذا واجهت أيًا من هذه العلامات والأعراض، خاصة إذا أصبحت أسوأ أو ظهرت لديك علامات تفاعلية حادة جديدة بعد الحقن اللاحقة. يمكن أن يكون علامة على رد فعل تحسسي، والذي يمكن أن يكون خطيرا.</p><p dir="RTL">&bull; <strong>انخفاض الجلوبيولين المناعي</strong>. قد يسبب كيسيمبتا انخفاضًا في بعض أنواع الأجسام المضادة. سيقوم مقدم الرعاية الصحية الخاص بك بإجراء اختبارات الدم للتحقق من مستويات الجلوبيولين المناعي في الدم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن نظر ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والملصق بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">احتفظ بالقلم (الأقلام) داخل العبوة الخارجية لحمايتها من الضَّوء. يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية). لا تعرضه للتَّجميد &nbsp;ولا ترج.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ماهي محتويات عقار كيسيمبتا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أوفاتوموماب. يحتوي كل قلم مُعبأ مسبقًا على 20 مجم من أوفاتوموماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: إل-أرجينين، أسيتات الصوديوم ثلاثي الهيدرات، كلوريد الصوديوم، بوليسوربات 80، إيديتات ثنائي الصوديوم ثنائي هيدرات، حمض الهيدروكلوريك (لضبط درجة الحموضة)، ماء للحَقْن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;ب.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong><strong>ما هو الشكل الصيدلاني لعقار كيسيمبتا ووصفه وحجم عبوته</strong></p><p dir="RTL">يكون عقار كيسيمبتا محلول للحقن صافيًا إلى غائم قليلًا، وعديم اللون إلى أصفر مائل إلى البني قليلًا.</p><p dir="RTL">عقار كيسيمبتا متاح في عبوات تحتوي على قلم سينسوريدي &nbsp;&nbsp;(SensoReady)واحد معبأ مسبقًا وفي عبوات متعددة تحتوي على 3 (3 عبوات بها قلم واحد) من أقلام سينسوريدي (SensoReady)المعبأة مسبقًا.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تم اعتماد هذه النشرة من قبل هيئة الغذاء والدواء الأمريكية في تاريخ 04/2024
‌هـ. للإبلاغ عن أية آثار جانبية:
•	المملكة العربية السعودية

المركز الوطني للتيقظ الدوائي (NPC) بالهيئة السعودية العامة للغذاء والدَّواء:

o	الفاكس: 00966112057662
o	مركز اتصال الهيئة السعودية العامة للغذاء والدواء: 19999
o	البريد الإلكتروني: npc.drug@sfda.gov.sa
o	الموقع على الإنترنت: https://ade.sfda.gov.sa 

قسم سلامة المرضى - شركة نوفارتس كونسلتينج إيه جي - المملكة العربية السعودية:
o	الهاتف المجاني: 8001240078
o	الهاتف: 966112658100+ 
o	فاكس: 966112658107+
البريد الإلكتروني: adverse.events@novartis.com  

للإبلاغ عن أي شكاوى: complaints.ksa@novartis.com


•	دول مجلس التَّعاون الخليجي الأخرى:
	يُرجى الاتصال بسلطات الاختصاص المعنية.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KESIMPTA 20mg/0.4ml solution for Injection in pre-filed pen 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KESIMPTA 20 mg solution for injection in pre-filled pen

Each pre-filled pen contains 20 mg ofatumumab in 0.4 ml solution.
Ofatumumab is a recombinant human monoclonal immunoglobulin G1 (IgG1) antibody that binds to human CD20 expressed on B-cells. Ofatumumab is produced in a murine NS0 cell line and consists of two IgG1 heavy chains and two kappa light chains with a molecular weight of approximately 146 kDa.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)
The solution is clear to slightly opalescent, and colourless to slightly brownish-yellow.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>KESIMPTA should be initiated by a physician experienced in the management of neurological conditions.</p><p>4.2.1&nbsp; Assessments Prior to First Dose of KESIMPTA</p><p><u>Hepatitis B Virus Screening</u></p><p>Prior to initiating KESIMPTA, perform Hepatitis B virus (HBV) screening. KESIMPTA is contraindicated in patients with active HBV confirmed by positive results for Hepatitis B surface antigen [HBsAg] and anti-HBV tests. For patients who are negative for HBsAg and positive for Hepatitis B core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with KESIMPTA (see section Special warnings and precautions for use).</p><p><u>Serum Immunoglobulins</u></p><p>Prior to initiating KESIMPTA, perform testing for quantitative serum immunoglobulins (see section Special Warnings and Precautions for use). For patients with low serum immunoglobulins, consult immunology experts before initiating treatment with KESIMPTA.</p><p><u>&nbsp;</u></p><p><u>Vaccinations</u></p><p>Because vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation until B-cell repletion, administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of KESIMPTA for live or live-attenuated vaccines, and whenever possible, at least 2 weeks prior to initiation of KESIMPTA for inactivated vaccines (see section Special warnings and precautions for use).</p><p><u>Posology</u></p><p>The recommended dosage of KESIMPTA is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; initial dosing of 20 mg by subcutaneous injection at Weeks 0, 1, and 2, followed by</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subsequent dosing of 20 mg by subcutaneous injection once monthly starting at Week 4.</p><p><em><u>&nbsp;</u></em></p><p><u>Missed Doses </u></p><p>If an injection of KESIMPTA is missed, it should be administered as soon as possible without waiting until the next scheduled dose. Subsequent doses should be administered at the recommended intervals.</p><p>&nbsp;</p><p><u>Special populations </u></p><p>&nbsp;</p><p>Elderly (aged 65 years and over)</p><p>No studies have been performed in elderly MS patients. Ofatumumab was studied in patients with RMS aged 18 to 55 years. Results from population pharmacokinetics suggest that dose adjustment is not required in elderly patients (see section Pharmacokinetic properties).</p><p>&nbsp;</p><p>Renal impairment</p><p>No specific studies of ofatumumab in patients with renal impairment have been performed.</p><p>Patients with mild renal impairment were included in clinical studies. There is no experience in patients with moderate and severe renal impairment. However, as ofatumumab is not excreted via urine it is not expected that patients with renal impairment require dose modification (see section Pharmacokinetic properties).</p><p>&nbsp;</p><p>Hepatic impairment</p><p>No studies of ofatumumab in patients with hepatic impairment have been performed.</p><p>Since hepatic metabolism of monoclonal antibodies such as ofatumumab is negligible, hepatic impairment is not expected to impact its pharmacokinetics. Therefore, it is not expected that patients with hepatic impairment require dose modification (see section Pharmacokinetic properties).</p><p>&nbsp;</p><p>&nbsp;</p><p>Paediatric population</p><p>The safety and efficacy of Kesimpta in children aged 0 to 18 years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Administer by subcutaneous injection only.</p><p>KESIMPTA is intended for patient self-administration by subcutaneous injection.</p><p>Administer KESIMPTA in the abdomen, thigh, or outer upper arm subcutaneously. Do not give injection into moles, scars, stretch marks or areas where the skin is tender, bruised, red, scaly or hard.</p><p>The first injection of KESIMPTA should be performed under the guidance of a healthcare professional (see section special Warnings and Precautions for use).</p><p>KESIMPTA Sensoready&reg; pens and syringes are for one-time use only and should be discarded after use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KESIMPTA is contraindicated in patients with:
•	Active HBV infection ([see section Special warnings and precautions for use).
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema [see section Special warnings and precautions for use]
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p><strong><u>Infections</u></strong></p><p>Serious, including life-threatening or fatal, bacterial, fungal, and new or reactivated viral infections have been observed during and following completion of treatment with anti-CD20 B-cell depleting therapies.<br />In KESIMPTA Study 1 and Study 2 [see Clinical Studies (14)], the overall rate of infections and serious infections in patients treated with KESIMPTA was similar to patients who were treated with teriflunomide (51.6% vs 52.7%,<br />and 2.5% vs 1.8%, respectively). The most common infections reported by KESIMPTA-treated patients in the randomized clinical relapsing MS (RMS) trials included upper respiratory tract infection (39%) and urinary tract infection (10%). Delay KESIMPTA administration in patients with an active infection until the infection is resolved</p><p>&nbsp;</p><p><u>Possible Increased Risk of Immunosuppressant Effects with Other Immunosuppressants</u></p><p>When initiating KESIMPTA after an immunosuppressive therapy or initiating an immunosuppressive therapy after KESIMPTA, consider the potential for increased immunosuppressive effects (see section Interaction with other medicinal products and other forms of interaction and Pharmacodynamics). KESIMPTA has not been studied in combination with other MS therapies.</p><p><em>Hepatitis B Virus</em></p><p><u>Reactivation</u></p><p>There were no reports of HBV reactivation in patients with MS treated with KESIMPTA. However, HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients being treated with ofatumumab for chronic lymphocytic leukemia (CLL) (at higher intravenous doses than the recommended dose in MS but for a shorter duration of treatment) and in patients treated with other anti-CD20 antibodies.</p><p><u>Infection</u></p><p>KESIMPTA is contraindicated in patients with active hepatitis B disease. Fatal infections caused by HBV in patients who have not been previously infected have occurred in patients being treated with ofatumumab for CLL (at higher intravenous doses than the recommended dose in MS but for a shorter duration of treatment). HBV screening should be performed in all patients before initiation of treatment with KESIMPTA. At a minimum, screening should include Hepatitis B surface antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) testing. These can be complemented with other appropriate markers as per local guidelines. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with KESIMPTA. These patients should be monitored and managed following local medical standards to prevent HBV infection or reactivation.</p><p><em>Progressive Multifocal Leukoencephalopathy</em></p><p>Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability.</p><p>Although no cases of PML have been reported for KESIMPTA in the RMS clinical studies, PML resulting in death has occurred in patients being treated with ofatumumab for CLL (at substantially higher intravenous doses than the recommended dose in MS but for a shorter duration of treatment). In addition, JCV infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies. At the first sign or symptom suggestive of PML, withhold KESIMPTA and perform an appropriate diagnostic evaluation. Magnetic reasonance imaging (MRI) findings may be apparent before clinical signs or symptoms. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.</p><p>If PML is confirmed, treatment with KESIMPTA should be discontinued.</p><p><em>Vaccinations</em></p><p>Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of KESIMPTA for live or live-attenuated vaccines, and whenever possible, at least 2 weeks prior to initiation of KESIMPTA for inactivated vaccines.</p><p>KESIMPTA may interfere with the effectiveness of inactivated vaccines.</p><p>The safety of immunization with live or live-attenuated vaccines following KESIMPTA therapy has not been studied. Vaccination with live or live-attenuated vaccines is not recommended during treatment and after discontinuation until B-cell repletion (see section Pharmacodynamics).</p><p>Vaccination of Infants Born to Mothers Treated with KESIMPTA During Pregnancy</p><p>In infants of mothers treated with KESIMPTA during pregnancy, do not administer live or live-attenuated vaccines before confirming the recovery of B-cell counts. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines.</p><p>Inactivated vaccines may be administered, as indicated, prior to recovery from B-cell depletion, but an assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.</p><p><em>Treatment of severely immunocompromised patients</em></p><p>KESIMPTA should not be given to patients in a severely immunocompromised state (e.g. significant neutropenia or lymphopenia).</p><p><strong>Injection-Related Reactions&nbsp;and Hypersensitivity Reactions</strong></p><p>KESIMPTA can result in systemic injection-related reactions and hypersensitivity reactions, which may be serious or life-threatening.</p><p>In Study 1 and Study 2, systemic and local injection reactions were reported in 21% and 11% of patients treated with KESIMPTA compared to 15% and 6% of patients treated with teriflunomide who received matching placebo injections, respectively (see section Undesirable effects and Pharmacodynamic properties)</p><p>Injection-related reactions with systemic symptoms observed in clinical studies occurred most commonly within 24 hours of the first injection, but were also observed with later injections. Symptoms observed included fever, headache, myalgia, chills, and fatigue, and were predominantly (99.8%) mild to moderate in severity. There were no life-threatening injection reactions in the RMS clinical studies.</p><p>&nbsp;</p><p>In the post-marketing setting, additional systemic injection-related reactions and hypersensitivity reactions have been reported, including anaphylaxis, angioedema, pruritus, rash, urticaria, erythema, bronchospasm, throat<br />irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, dizziness, nausea, and tachycardia. Most cases were non-serious and occurred with the first injection. Most serious cases resulted in<br />permanent discontinuation of KESIMPTA.</p><p><br />Symptoms of systemic injection-related reactions may be clinically indistinguishable from acute hypersensitivity reactions. A hypersensitivity reaction may occur with any injection. New or more severe symptoms compared to<br />those experienced with previous injections should prompt consideration of a potential hypersensitivity reaction.</p><p><br />Only limited benefit of premedication with corticosteroids, antihistamines, or acetaminophen was observed in RMS clinical studies. The first injection of KESIMPTA should be performed under the guidance of an appropriately<br />trained healthcare professional. If systemic injection-related reactions occur, initiate appropriate therapy. Patients who experience symptoms of systemic injection-related reactions or hypersensitivity reactions with KESIMPTA<br />should be instructed to seek immediate medical attention.</p><p><br />If a hypersensitivity reaction or life-threatening systemic injection-related reaction occurs, immediately and permanently discontinue KESIMPTA [see Section Contraindications]. If restarting KESIMPTA after a severe (but<br />not life-threatening) systemic injection-related reaction or other event after which rechallenge is considered appropriate, administer the next KESIMPTA injection under clinical observation. If a mild to moderate injectionrelated<br />reaction occurs, consider rechallenge under clinical observation.</p><p><br />Local injection-site reaction symptoms observed in clinical studies included erythema, swelling, itching, and pain. If local injection-related reactions occur, symptomatic treatment is recommended.</p><p>&nbsp;</p><p><strong>Reduction in Immunoglobulins&nbsp; </strong></p><p>As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 7.7% of patients treated with KESIMPTA compared to 3.1% of patients treated with teriflunomide in RMS clinical trials (see section Undesirable effects)Treatment was discontinued because of decreased immunoglobulins in 3.4% of patients treated with KESIMPTA and in 0.8% of patients treated with teriflunomide. No decline in immunoglobulin G (IgG) was observed at the end of the study. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing KESIMPTA therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.&nbsp; <strong> </strong></p><p><strong>Fetal Risk </strong></p><p>Based on animal data, KESIMPTA can cause fetal harm due to B-cell lymphopenia and reduce antibody response in offspring exposed to KESIMPTAin utero. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception while receiving KESIMPTA and for at least 6 months after the last dose (see section Interaction with other medicinal products and other forms of interaction).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ofatumumab does not share a common clearance pathway with chemical drugs that are metabolized by the cytochrome P450 system or other drug metabolizing enzymes. Additionally, there is no evidence that CD20 monoclonal antibodies are involved in the regulation of the expression of drug metabolizing enzymes. Interactions between KESIMPTA and other medicinal products have not been investigated in formal studies.</p><p><u>Immunosuppressive or Immune-Modulating Therapies</u></p><p>Concomitant usage of KESIMPTA with immunosuppressant drugs, including systemic corticosteroids, may increase the risk of infection. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with KESIMPTA.</p><p>When switching from therapies with immune effects, the duration and mechanism of action of these therapies should be taken into account because of potential additive immunosuppressive effects when initiating KESIMPTA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy/ Contraception in males and females</u></p><p>&nbsp;</p><p>Females of childbearing potential should use effective contraception while receiving KESIMPTA and for 6 months after the last treatment of KESIMPTA <em>(see section special Warnings and Precautions for use and Pharmacokinetic properties)</em></p><p>&nbsp;</p><p><u>Risk Summary </u></p><p>There are no adequate data on the developmental risk associated with the use of KESIMPTA in pregnant women. Ofatumumab may cross the placenta and cause fetal B-cell depletion based on findings from animal studies [see section Interaction with other medicinal products and other forms of interaction (Data)].</p><p>Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. B-cell levels in infants following maternal exposure to KESIMPTA have not been studied in clinical trials. The potential duration of B-cell depletion in infants exposed to ofatumumab in utero, and the impact of B-cell depletion on the safety and effectiveness of vaccines, are unknown. Avoid administering live vaccines to neonates and infants exposed to KESIMPTA in utero until B-cell recovery occurs (see section special Warnings and Precautions for use and Pharmacodynamics).</p><p>Following administration of ofatumumab to pregnant monkeys, increased mortality, depletion of B-cell populations, and impaired immune function were observed in the offspring, in the absence of maternal toxicity, at plasma levels substantially higher than that in humans &nbsp;[see section Interaction with other medicinal products and other forms of interaction (Data)].</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.&nbsp;&nbsp;</p><p>&nbsp;</p><p><u>Data</u></p><p>Animal Data</p><p>Intravenous administration of ofatumumab (weekly doses of 0, 20, or 100 mg/kg) to pregnant monkeys during the period of organogenesis (gestations days 20 to 50) resulted in no adverse effects on embryofetal development; however, B-cell depletion was observed in fetuses at both doses when assessed on gestation day 100. Plasma exposure (Cave) at the no-effect dose (100 mg/kg) for adverse effects on embryofetal development was greater than 5000 times that in humans at the recommended human maintenance dose of 20 mg. A no-effect dose for effects on B-cells was not identified; plasma exposure (Cave) at the low-effect dose (20 mg/kg) was approximately 780 times that in humans at the recommended human maintenance dose (RHMD) of 20 mg/month.&nbsp;</p><p>Intravenous administration of ofatumumab (5 weekly doses of 0, 10, and 100 mg/kg, followed by biweekly doses of 0, 3, and 20 mg/kg) to pregnant monkeys throughout pregnancy resulted in no adverse effects on the development of the offspring. However, postnatal death, B-cell depletion, and impaired immune function were observed in the offspring at the high dose. The deaths at the high dose were considered secondary to B-cell depletion. Plasma exposure (Cave) in dams at the no-effect dose (100/20 mg/kg) for adverse developmental effects was approximately 500 times that in humans at RHMD. A no-effect level for&nbsp; mortality and immune effects in offspring was not established because of the limited number of evaluable offspring at the low dose.</p><p><u>&nbsp;</u></p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>Risk Summary</p><p>There are no data on the presence of ofatumumab in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Human IgG is excreted in human milk, and the potential for absorption of ofatumumab to lead to B-cell depletion in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for KESIMPTA and any potential adverse effects on the breastfed infant from KESIMPTA or from the underlying maternal condition.</p><p><u>&nbsp;</u></p><p><u>Impairment of Fertility</u></p><p>No effects on reproductive parameters, including hormones, menstrual cycle, sperm analysis, or histopathological evaluation of reproductive organs, were observed in male or female monkeys administered ofatumumab by intravenous injection (5 weekly doses of 0, 10, and 100 mg/kg, followed by biweekly doses of 0, 3, and 20 mg/kg). Plasma exposures (Cave) at the high dose tested in monkey are greater than 500 times that in humans at the recommended human maintenance dose of 20 mg/month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kesimpta expected to have no or negligible influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a.Summary of the safety profile</u></p><p>The following clinically significant adverse reactions are discussed in greater detail elsewhere in the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections (see section Special warnings and precautions for use)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection-Related Reactions&nbsp;and Hypersensitivity Reactions (see section Special warnings and precautions for use)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Reduction in Immunoglobulins (see section Special warnings and precautions for use)</p><p>4.8.1&nbsp; Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>Approximately 1500 patients with RMS received KESIMPTA in clinical studies. In Study 1 and Study 2, 1882 patients with RMS were randomized, 946 of whom were treated with KESIMPTA for a median duration of 85 weeks; 33% of patients receiving KESIMPTA were treated for up to 120 weeks (see section Pharmacodynamic properties). The most common adverse reactions occurring in greater than 10% of patients treated with KESIMPTA and more frequently than in patients treated with teriflunomide were upper respiratory tract infections, injection-related reactions (systemic), headache, and injection-site reactions (local). The most common cause of discontinuation in patients treated with KESIMPTA was low immunoglobulin M (3.3%), defined in trial protocols as IgM at 10% below the lower limit of normal (LLN).</p><p>&nbsp;</p><p><u>b.Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Table 1 summarizes the adverse drug reactions that occurred in Study 1 and Study 2.</p><p>Table 1: Adverse Reactions in Patients with RMS with an Incidence of at Least 5% with KESIMPTA and a Greater Incidence Than Teriflunomide (Pooled Study 1 and Study 2)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Adverse Reactions</p></td><td><p>KESIMPTA 20 mg</p><p>N = 946</p><p>%</p></td><td><p>Teriflunomide 14 mg</p><p>N = 936</p><p>%</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infections<sup>a</sup></p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td style="vertical-align:top"><p>Injection-related reactions (systemic)</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site reactions (local)</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:bottom"><p>Urinary tract infection</p></td><td><p>10</p></td><td><p>8</p></td></tr><tr><td style="vertical-align:bottom"><p>Back pain</p></td><td><p>8</p></td><td><p>6</p></td></tr><tr><td style="vertical-align:bottom"><p>Blood immunoglobulin M decreased</p></td><td><p>6</p></td><td><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>Includes the following: nasopharyngitis, upper respiratory tract infection, influenza, sinusitis, pharyngitis, rhinitis, viral upper respiratory infection, tonsillitis, acute sinusitis, pharyngotonsillitis, laryngitis, pharyngitis streptococcal, viral rhinitis, sinusitis bacterial, tonsillitis bacterial, viral pharyngitis, viral tonsillitis, chronic sinusitis, nasal herpes, tracheitis.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p><u>c.Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><u>Injection-Related Reactions and Injection-Site Reactions</u></p><p>The incidence of injection-related reactions (systemic) was highest with the first injection (14.4%), decreasing with subsequent injections (4.4% with second, less than 3% with third injection). Injection-related reactions were mostly (99.8%) mild to moderate in severity. Two (0.2%) patients treated with KESIMPTA reported serious injection-related reactions. There were no life-threatening injection-related reactions. Most frequently reported symptoms (2% or greater) included fever, headache, myalgia, chills, and fatigue.</p><p>In addition to systemic injection-related reactions, local reactions at the administration site were very common. Local injection-site reactions were all mild to moderate in severity. The most frequently reported symptoms (2% or greater) included erythema, pain, itching, and swelling <em>[see section special Warnings and Precautions for use).</em></p><p><u>Laboratory Abnormalities</u></p><p><em>Immunoglobulins</em></p><p>In Study 1 and Study 2, a decrease in the mean level of IgM was observed in KESIMPTA-treated patients but was not associated with an increased risk of infections <em>(see section special Warnings and Precautions for use).</em> In 14.3% of patients in Study 1 and Study 2, treatment with KESIMPTA resulted in a decrease in a serum IgM that reached a value below 0.34 g/dL. KESIMPTA was associated with a decrease of 4.3% in mean IgG levels after 48 weeks of treatment and an increase of 2.2% after 96 weeks.</p><p>4.8.2&nbsp; Immunogenicity</p><p>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medication, and the underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other ofatumumab products may be misleading.</p><p>Treatment induced anti-drug antibodies (ADAs) were detected in 2 of 914 (0.2%) KESIMPTA-treated patients; no patients with treatment enhancing or neutralizing ADAs were identified. There was no impact of positive ADA titers on PK, safety profile or B-cell kinetics in any patient; however, these data are not adequate to assess the impact of ADAs on the safety and efficacy of KESIMPTA.</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o SFDA call center: 19999</p><p>o E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&bull; To report any complaint(s) :complaints.ksa@novartis.com</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p><p>&nbsp;</p><p>4.8.3 Postmarketing Experience<br />The following adverse reactions have been identified during post approval use of KESIMPTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate<br />their frequency or establish a causal relationship to drug exposure.</p><p>Immune System: Hypersensitivity reactions [see Section Special warnings and precautions for use]</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of overdose have been reported in RMS clinical studies.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: selective immunosuppressants, ATC code:&nbsp;L04AG12</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p><em><u>&nbsp;</u></em></p><p>The precise mechanism by which ofatumumab exerts its therapeutic effects in MS is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.</p><p>&nbsp;</p><p><u>Pharmacodynamics</u></p><p>&nbsp;</p><p><u>B-cell Depletion</u></p><p>For B-cell counts, assays for CD19+ B-cells are used because the presence of KESIMPTA interferes with the CD20 assay. In Study 1 and Study 2, KESIMPTA administered as recommended, resulted in a reduction of CD19+ B-cells to below the LLN in 77.0% and 78.8% of patients, respectively, one week after treatment initiation, and in 95.0% and 95.8% of patients, respectively, two weeks after treatment initiation [see Dosage and Administration (2.2) and Clinical Studies (14)]. In Study 1 and Study 2, at Week 12, 99.3% to 99.5% of patients had CD19+ B-cell counts below LLN. The CD19+ B-cell counts remained below LLN for approximately 97% of patients in Study 1 and 92% of patients in Study 2 from 12 weeks through 120 weeks while on KESIMPTA treatment.</p><p>In a study of bioequivalence using the same dosing regimen as in Study 1 and Study 2, before initiation of the maintenance phase, total CD19+ B-cell levels below the defined threshold of 10&nbsp;cells/&micro;L were achieved in 94% of patients starting at Week 4 and 98% of patients at Week 12.</p><p><u>B-cell Repletion</u></p><p>Data from Studies 1 and 2 indicate a median time to B-cell recovery to either LLN or baseline value of 24.6 weeks posttreatment discontinuation. Pharmacokinetics and pharmacodynamics modeling and simulation for B-cell repletion<br />corroborate these data, predicting median time to B-cell recovery to LLN of 23 weeks post-treatment discontinuation</p><p>&nbsp;</p><p><u>Clinical studies</u></p><p><u>&nbsp;</u></p><p>The efficacy of KESIMPTA was demonstrated in two randomized, double-blind, double-dummy, active comparator-controlled clinical trials of identical design, in patients with relapsing forms of MS [Study 1 (NCT02792218) and Study 2 (NCT02792231)]. Both studies enrolled patients with at least one relapse in the previous year, 2 relapses in the previous 2 years, or the presence of a T1 gadolinium-enhancing (GdE) lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5.&nbsp;</p><p>&nbsp;</p><p>Patients were randomized to receive either KESIMPTA, 20 mg subcutaneously on Days 1, 7, and 14, followed by 20 mg every 4 weeks thereafter starting at Week 4 with a daily oral placebo, or the active comparator, teriflunomide, at a dose of 14 mg orally once daily with a placebo administered subcutaneously on Days 1, 7, 14, and every 4 weeks thereafter. The treatment duration for an individual patient was variable based on when the end of study criteria were met. The maximal duration of treatment for an individual patient was 120 weeks. Neurologic evaluations were performed at baseline, every 3 months during blinded treatment, and at the time of a suspected relapse. Brain MRI scans were performed at baseline, 1 and 2 years.</p><p>&nbsp;</p><p>The primary endpoint of both trials was the annualized relapse rate (ARR) over the treatment period. Additional outcome measures included: 1) the time to 3-month confirmed disability progression for the pooled populations, 2) the number of T1 GdE lesions per scan at Weeks 24, 48, and 96, and 3) the annualized rate of new or enlarging T2 MRI lesions. Disability progression was defined as an increase in EDSS of at least 1.5, 1, or 0.5 points in patients with a baseline EDSS of 0, 1 to 5, or 5.5 or greater, respectively.</p><p>&nbsp;</p><p>In Study 1, a total of 927 patients were randomized to receive KESIMPTA (n = 465) or teriflunomide (n = 462). Of those randomized to KESIMPTA, 90% completed the study; of those randomized to teriflunomide, 81% completed the study. Demographics and disease characteristics were balanced across treatment arms. The mean age was 38 years, 89% were White, and 69% were female. The mean time since MS diagnosis was 5.7 years and the median EDSS score at baseline was 3.0; 60% had been treated with a non-steroid therapy for MS. At baseline, the mean number of relapses in the previous year was 1 and the mean number of T1 GdE lesions on MRI scan was 1.5.</p><p>&nbsp;</p><p>In Study 2, a total of 955 patients were randomized to receive KESIMPTA (n = 481) or teriflunomide (n = 474). Of those randomized to KESIMPTA, 83% completed the study; of those randomized to teriflunomide, 82% completed the study. Demographics and disease characteristics were balanced across treatment arms. The mean age was 38 years, 87% were White, and 67% were female. The mean time since MS diagnosis was 5.5 years and the median EDSS score at baseline was 2.5; 61% had been treated with a non-steroid therapy for MS. At baseline, the mean number of relapses in the previous year was 1.3, and the mean number of T1 GdE lesions on MRI scan was 1.6.</p><p>In both studies, KESIMPTA significantly lowered the ARR compared to teriflunomide.</p><p>KESIMPTA significantly reduced the risk of 3-month confirmed disability progression compared to teriflunomide.</p><p>&nbsp;</p><p>KESIMPTA significantly reduced the number of T1 GdE lesions and the rate of new or enlarging T2 lesions in both studies.</p><p>&nbsp;</p><p>Key results for Study 1 and Study 2 are presented in Table 2 and Figure 1.</p><p>&nbsp;</p><p><strong>Table 2: </strong><strong>Key Clinical and MRI Endpoints From Study 1 and Study 2 </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Endpoints</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 1 </strong></p></td><td colspan="3"><p><strong>Study 2 </strong></p></td></tr><tr><td style="vertical-align:top"><p>KESIMPTA 20&nbsp;mg</p><p>(n = 465)</p></td><td style="vertical-align:top"><p>Teriflunomide 14&nbsp;mg</p><p>(n = 462)</p></td><td style="vertical-align:top"><p>KESIMPTA 20&nbsp;mg</p><p>(n = 481)</p></td><td colspan="2" style="vertical-align:top"><p>Teriflunomide 14&nbsp;mg</p><p>(n = 474)</p></td></tr><tr><td colspan="6"><p><strong>Clinical Endpoints</strong></p></td></tr><tr><td><p>Annualized relapse rate (Primary Endpoint)</p></td><td><p>0.11</p></td><td><p>0.22</p></td><td><p>0.10</p></td><td colspan="2"><p>0.25</p></td></tr><tr><td><p>Relative Reduction</p></td><td colspan="2"><p>51% (p &lt; 0.001)</p></td><td colspan="3"><p>58% (p &lt; 0.001)</p></td></tr><tr><td><p>Proportion of Patients with 3‑month Confirmed Disability Progression<sup>a,b</sup></p><p>Relative Risk Reduction</p></td><td colspan="5"><p>10.9% KESIMPTA vs 15.0% teriflunomide</p><p>&nbsp;</p><p>34.4% (p = 0.003)</p></td></tr><tr><td colspan="6"><p><strong>MRI Endpoints</strong></p></td></tr><tr><td><p>Mean number of T1 Gd-enhancing lesions per MRI scan</p></td><td><p>0.01</p></td><td><p>0.46</p></td><td><p>0.03</p></td><td colspan="2"><p>0.52</p></td></tr><tr><td><p>Relative Reduction</p></td><td colspan="2"><p>98% (p &lt; 0.001)</p></td><td colspan="3"><p>94% (p &lt; 0.001)</p></td></tr><tr><td><p>Number of new or enlarging T2 lesions per year</p></td><td><p>0.72</p></td><td><p>4.00</p></td><td><p>0.64</p></td><td colspan="2"><p>4.16</p></td></tr><tr><td><p>Relative Reduction</p></td><td colspan="2"><p>82% (p &lt; 0.001)</p></td><td colspan="3"><p>85% (p &lt; 0.001)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>Disability progression was defined as an increase in EDSS of at least 1.5, 1, or 0.5 points in patients with a baseline EDSS of 0, 1 to 5, or 5.5 or greater, respectively.</p><p><sup>b</sup>Prospective pooled analysis of Studies 1 and 2. Proportion of patients with 3-month confirmed disability progression refers to Kaplan-Meier estimates at Month 24.</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure 1 : Time to First 3-month Confirmed Disability Progression by Treatment Full Analysis Set</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453pt;
 height:288.75pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg"
  o:href="cid:image001.jpg@01D6764F.E9691400"/>
</v:shape><![endif]--><img width="604" height="385" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg" /></p><p>&nbsp;</p><p>A similar effect of KESIMPTA on the key efficacy results compared to teriflunomide was observed across the two<br />studies in exploratory subgroups defined by sex, age, body weight, prior non-steroid MS therapy, and baseline<br />disability and disease activity.</p><p><br /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:453.55pt;height:279.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>A subcutaneous dose of 20 mg every 4 weeks leads to a mean AUCtau of 483 mcg h/mL and a mean Cmax of 1.43 mcg/mL at steady state.</p><p>After subcutaneous administration, ofatumumab is believed to be predominantly absorbed via the lymphatic system similarly to other therapeutic monoclonal antibodies.</p><p>Distribution</p><p>The volume of distribution at steady-state was estimated to be 5.42 L following subcutaneous administration of repeated KESIMPTA 20 mg dose.</p><p>Elimination</p><p>Biotransformation/metabolism</p><p>Ofatumumab is a protein for which the expected metabolic pathway is degradation to small peptides and amino acids by ubiquitous proteolytic enzymes.</p><p>Excretion</p><p>Ofatumumab is eliminated by both linear catabolic pathways and a non-linear B-cell mediated pathway, resulting<br />in non-constant elimination half-life. Initially, a higher baseline B-cell count results in greater B-cell-mediated<br />elimination and shorter ofatumumab half-life. As the B-cells are depleted, the catabolic pathway predominates,<br />resulting in a relatively longer ofatumumab half-life compared to earlier in therapy when both elimination pathways<br />were available.<br />Following B cell depletion, clearance was estimated to be 0.34 L/day following repeated subcutaneous<br />administration of KESIMPTA 20 mg injections. The half-life at steady state was estimated to be approximately 16<br />days following subcutaneous administration of repeated KESIMPTA 20 mg dose.<br />Ofatumumab, a monoclonal antibody, is not likely to undergo renal excretion.</p><p><u>Special populations</u></p><p>The following population characteristics do not have a clinically meaningful effect on the pharmacokinetics of ofatumumab: body weight, sex, age, race, or baseline B-cell count.</p><p>&nbsp;</p><p><u>Pediatric Use</u></p><p>Safety and effectiveness in pediatric patients have not been established.</p><p><u>&nbsp;</u></p><p><u>Geriatric Use</u></p><p>Clinical studies of KESIMPTA did not include sufficient numbers of geriatric patients to determine whether they respond differently from younger subjects.</p><p>&nbsp;</p><p><u>Patients with Renal/Hepatic Impairment</u></p><p>Pharmacokinetics of ofatumumab in patients with renal or hepatic impairment have not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>NONCLINICAL TOXICOLOGY</strong></p><p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p><u>Carcinogenesis</u></p><p>No carcinogenicity studies have been conducted to assess the carcinogenic potential of ofatumumab.</p><p><u>Mutagenesis</u></p><p>No studies have been conducted to assess the mutagenic potential of ofatumumab. As an antibody, ofatumumab is not expected to interact directly with DNA.</p><p><u>Impairment of Fertility</u></p><p>No effects on reproductive parameters, including hormones, menstrual cycle, sperm analysis, or histopathological evaluation of reproductive organs, were observed in male or female monkeys administered ofatumumab by intravenous injection (5 weekly doses of 0, 10, and 100 mg/kg, followed by biweekly doses of 0, 3, and 20 mg/kg). Plasma exposures (Cave) at the high dose tested in monkey are greater than 500 times that in humans at the recommended human maintenance dose of 20 mg/month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L-arginine 4mg/0.4ml</p><p>Sodium acetate trihydrate 2.722mg/0.4ml</p><p>Sodium chloride 1.192 mg/0.4ml</p><p>Polysorbate 80 0.080 mg/0.4ml</p><p>Disodium edetate dihydrate 0.007 mg/0.4ml</p><p>Hydrochloric acid (for pH adjustment) QS</p><p>Water for injections up to 408ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Kesimpta 20 mg solution for injection in pre-filled pen</u></p><p><u>&nbsp;</u></p><p>Store in refrigerator at (2&ordm;C to 8&ordm;C).</p><p>Keep the product in the original carton to protect from light.</p><p>Do not freeze.</p><p>Do not shake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Kesimpta 20 mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>is supplied in a single-use glass syringe, equipped with a stainless steel needle, a plunger stopper and a rigid needle shield, containing 0.4 ml solution. The syringe is assembled into an auto-injector (SensoReady pen).</p><p>Kesimpta is available in unit packs containing 1 pre-filled SensoReady pen and in multipacks containing 3 (3 packs of 1) pre-filled SensoReady pens.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The KESIMPTA &ldquo;Instructions for Use&rdquo; for each presentation contains more detailed instructions on the preparation of KESIMPTA.</p><p>Before administration, remove KESIMPTA Sensoready pen or KESIMPTA prefilled syringe from the refrigerator and allow KESIMPTA to reach room temperature for about 15 to 30 minutes. DO NOT remove the needle cover while allowing the prefilled syringe to reach room temperature.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particles or is cloudy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by USFDA in Apr 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>